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Abstract
Background: Overexpression of matrix-metalloproteinases (MMPs) has been shown to lead to tissue damage in
equine recurrent airway obstruction (RAO), as a misbalance with their natural inhibitors, the tissue inhibitors of
metalloproteinases (TIMPs), occurs. This favors irreversible pulmonary fibrosis formation. Increased levels of MMPs,
TIMPs or altered ratios between them can be used as biomarkers of respiratory disease. We hypothesized that
levels of MMPs, TIMPs and their ratios correlate with improvement in clinical findings and bronchoalveolar lavage
fluid (BALF) cytology after 10 days of inhalative glucocorticoid therapy and environmental dust reduction (EDR)
and may be used to monitor treatment success.
Ten horses with a history of RAO participated in a prospective clinical study. Clinical and cytological scoring was
performed before and after inhalative therapy using budesonide (1500 μg BID over 10 days) and EDR (bedding of
wood shavings and wet hay as roughage). Gelatin zymography was performed for qualitative and semi-quantitative
evaluation of MMP-2 and MMP-9 in BALF supernatant, while fluorimetry was used to evaluate MMP-8 activity.
Additionally, specific equine ELISA assays were used for quantitative assessment of MMP-2, MMP-9, TIMP-1 and
TIMP-2.
Results: A significant reduction in the total and several single parameters of the clinical score were found after
10 days of inhalative therapy and EDR. The concentrations of MMP-2, MMP-9, TIMP-1 and TIMP-2 (ELISA) as well
as their activities (MMP-2 and MMP-9 zymography and MMP-8 fluorimetry) were significantly decreased after therapy.
Significant improvements in MMP-8/TIMP-1 and MMP-8/TIMP-2 ratios were also found, differences between other
ratios before and after therapy were insignificant.
Conclusions: Metalloproteinases and their inhibitors, in particular MMP-9 and TIMP-2, are valuable markers for
clinical improvement in RAO.
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Background
Severe equine asthma, commonly known as recurrent
airway obstruction (RAO), is a very common pneumopathy
in middle-aged to older horses with a prevalence of about
14% in the general horse population [1]. Older studies even
found an incidence over 50% of this respiratory disease [2].
Thus, RAO is considered an important problem requiring
veterinary attention as it leads to decreased performance
capacity and major economic losses [3].
Equine RAO resembles human asthma and COPD in
many ways. In all of them, so called remodeling of the
pulmonary tissue occurs, which includes reduction of
bronchial luminal caliber, smooth muscle hypertrophy,
peribronchiolar fibrosis formation and airway epithelial
cell hyperplasia, all impeding gas exchange [4, 5]. Control
of remodeling may be the key to effective therapy and
long-term success of managing these patients [6].
The extracellular matrix (ECM) stabilizes the inner
structures of the lung, for which collagen is the most im-
portant ECM component. Therefore, the ECM is essential
to insure the efficacy of gas exchange. To allow for growth
and physiologic tissue repair, it underlies a continuous
turnover, but a physiologic balance between synthesis and
degradation needs to be maintained. Cleavage of ECM
components takes place by zinc-depentant endopepti-
dases, so called matrix-metalloproteinases (MMPs) and is
controlled by their natural inhibitors, the tissue inhibitors
of matrix metalloproteinases (TIMPs) [6, 7]. Over-
whelming proteolytic degradation in consequence of a
dysbalance of MMP and TIMP activity leads to an inflam-
matory response and ultimately fibrosis formation [8, 9].
Several studies have been published focusing on MMP
levels in equine RAO. Increased collagenolytic activity,
as indicated by MMP-8 concentrations, was found in
tracheal epithelium lining fluid (TELF) [10]. Levels of
MMP-8 and MMP-13 were positively correlated with
type-I collagen degradation [11].
Markedly increased elastinolytic activity in TELF, indi-
cated by MMP-2 and −9, was also found in RAO [12, 13],
but other authors found no disease-associated increase of
MMP-2 levels and concluded that its major role may be
the physiologic ECM turnover [14]. MMP-9 on the other
hand shows very low levels in health, but increases dra-
matically during exacerbations of asthma and RAO as well
as in idiopathic pulmonary fibrosis [15].
While levels of MMPs have been studied intensively in
RAO, not much is known about their natural inhibitors,
in particular TIMP-1 and TIMP-2, as well as the course
of MMPs and TIMPs under different forms of therapy.
The inhibitory effect of different tetracyclines, flunixin
meglumine and pentoxifylline on elastinolytic activity
after intravenous infusion of lipopolysaccharide (LPS)
was evaluated [16]. All MMP inhibitors significantly
decreased MMP activities, but pentoxifylline and
oxytetracycline appeared to be the most effective.
Collagenase activity also could be reduced by doxycyc-
line inhibition in tracheal aspirates [10]. These authors
concluded that MMP inhibitors might be a valuable
new treatment approach to equine RAO. A similar
effect was found in a clinical trial in human medicine,
in which COPD patients with stable symptoms showed
significant improvement in lung function after 4-weeks
of doxycycline treatment [17].
Before testing MMP inhibitors in a clinical setting, we
were interested in the course of MMPs and TIMPs under
the cornerstone of RAO therapy, namely environmental
dust reduction in combination with anti-inflammatory
glucocorticoids, which were given in an inhalative
approach to achieve high local concentrations in the lung.
The focus of this study was the evaluation of possible cor-
relations between clinical and cytological parameters with
MMP-2, −8 and −9 as well as TIMP1- and −2 activities
and concentrations before and after 10 days of inhala-




10 horses (4 geldings, 6 mares, age 16.5 ± 4.3 years,
BDW 481 ± 80.4 kg) with a history of RAO were examined
to evaluate the current disease status using a validated
clinical score system, recommended by an international
workshop [18, 19] and modified by including cytology of
BALF instead of tracheal aspirates [20], the previous diag-
nosis was confirmed (Table 1). Horses in remission, not
meeting the inclusion criteria for RAO exacerbation,
but still showing parameters above reference values, were
included into the study, as these patients account for a
large part of our hospital population and often show fur-
ther improvement under therapy.
BALF collection and processing
Under local anesthesia using 20 ml of 2% lidocaine1
applied to the main bronchi, bronchoalveolar lavage
was performed using a silicone catheter.2 Five hundred
milliliters of pre-warmed phosphate buffered saline3
were infused and immediately aspirated. BALF was
divided into 2 aliquots for cytological and biochemical
examination. After centrifugation4 (250 g, 10 min at
4 °C) the BALF supernatant was kept at −80 °C until
further analysis. Cytology was performed using
Wright-Giemsa staining and counting 500 cells at 500x
magnification.
Gelatine zymography of elastases
Zymography was performed5,6 following the manufac-
turer’s instructions. Human MMP-2 and MMP-9 controls
were used together with a multicolor broad protein range
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protein ladder as a control on each gel. Also, a sample of a
healthy control horse (samples of a previous study) was ap-
plied to each gel to compare the signals to affected horses.
Gels were scanned for digital analysis by densitometry using
digital image analyzing software7 to quantify the bands
objectively as described previously [21].
ELISA of MMPs and TIMPs
Commercially available ELISA systems were used for
quantification of MMP-2, MMP-9, TIMP-1 and TIMP-2
concentrations.891011 Duplicate standards and samples
were measured following the manufacturer’s instructions
and absorbance measured with an ELISA microplate
reader12 at 450 nm.
Fluorimetry MMP-8 assay
For the MMP-8 assay13 the manufacturer’s instructions
were followed. Negative controls containing assay buffer
and positive controls using recombinant human purified
MMP-8 were included.
Inhalation therapy
Inhalation therapy was performed twice daily at a dosage
of 1500 μg budesonide (Pulmicort™ suspension)14 using
an automatic inhalation device15. Although the study
participants had been under environmental dust reduc-
tion (wood shavings as bedding and wet hay as roughage)
at their home stables prior to the study, they were stabled
in the clinic for overall 16 days to ensure the same
conditions concerning stabling and application of
inhalation therapy for all animals. During the phase of
inhalation therapy a daily clinical examination ensured
that no horse was suffering from complications or
showed clinical signs of respiratory infection.
Check-up examination
After 10 days of inhalation therapy, the horses were
examined following the same protocol as for the prepar-
ticipation examination exclusive of thoracic radiography.
Afterwards, they were discharged from the clinic with
instructions to the owners concerning further manage-
ment and therapy.
Statistical analysis
Statistical analysis was performed using SPSS Statistics16
and results were expressed as mean ± standard deviation
(SD). As parts of data were not found to be normally
distributed using the Shapiro Wilks Test, non-parametric
tests were used for the entire analysis. The level of signifi-
cance was set at P < 0.05.
Spearman rank correlation coefficients were calculated
between clinical and cytological parameters, MMP and
TIMP concentrations or activities, respectively. The level
of significance was set at P < 0.05.
The Wilcoxon signed ranks test was used to analyze
differences before and after budesonide inhalation in
combination with environmental dust reduction Again,
the level of significance was set at P < 0.05.
Table 1 Clinical scoring system, modified from Ohnesorge et al. (1998): The highest score given in each subcategory counts as
maximum points for this subcategory, maximum points of subcategories are summed up to gain the total score number
Score Max. Points
1. Coughing No cough after manual compression of larynx 0 1
from history, spontaneously or induced 1
2. Dyspnoea at rest moderately increased abdominal effort 1 3
Nostril flare 3
Hypertrophy of abdominal muscles 3
3. Percussion lung field >1 hand increase 1 2
>2 hands increase 2
4. Lung auscultation Wheezes and crackles 2 2
5. Endoscopy Significantly increased secretions with moderate viscosity 1 2
Highly increased secretions with high viscosity 2
Marked thickening of tracheal bifurcation [52] 1




7. Blood gas analysis PAO2-PaO2: 0–7 mmHg 0 2
PAO2-PaO2: 7–14 mmHg 1
PAO2-PaO2: >14 mmHg 2
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Results
Clinical scoring
The anamnestic diagnosis of RAO was confirmed for all
10 horses. 7 horses were classified RAO in exacerbation,
3 in partial remission. All were subjected to treatment.
The total examination score before and after therapy
showed a significant difference before and after therapy
(P = 0.005) with the endoscopy score being the single
parameter of highest significance (P = 0.007).
Inhalation therapy and environmental dust reduction
resulted in significantly decreased neutrophil ratio after
therapy (25.7 ± 19.4%) compared to before therapy
(42.92 ± 27%). As neutrophils decreased (P = 0.013), the
relative percentage of macrophages increased (P = 0.022)
from 32.77 ± 18.7% before therapy to 45 ± 16.57% after
therapy.
Results of clinical scoring are shown in Table 2.
MMP-2 ELISA
The concentration of MMP-2 was significantly decreased
after therapy (3.54 pg/ml ± 0.71 pg/ml) compared to
before therapy (4.93 pg/ml ± 0.91 pg/ml, P = 0.005).
MMP-2 activity in BALF detected by gelatin zymography
was significantly decreased after therapy (5827.45 ±
5250.42) compared to that before therapy (12570.98 ±
9164.32, P = 0.028).
MMP-9 ELISA
MMP-9 concentration in BAL was significantly decreased
after therapy (282.29 ng/ml ± 101.19 ng/ml) compared to
before therapy (414.59 ng/ml ± 119.6 ng/ml, P = 0.005).
The MMP-9 activity in gelatin zymography was signifi-
cantly decreased after therapy (2942.95 ± 2440.24) com-
pared to before therapy (11176.68 ± 11255.3, P = 0.022).
Examples of MMP-2 and MMP-9 zymography before
and after therapy are shown in Figs. 1a and b.
TIMP-1 ELISA
TIMP-1 concentration was significantly decreased after
therapy (249.78 ± 59.56 pg/ml) compared to before therapy
(308.80 ± 7.44 pg/ml, P = 0.005).
TIMP-2 ELISA
TIMP-2 concentration was also significantly decreased
after therapy (18.76 ± 2.79 ng/ml) compared to before
therapy (26.20 ± 1.49 ng/ml, P = 0.002).
MMP-8 fluorimetry
The activity of MMP-8 was significantly decreased after
therapy (0.10 RFU ± 0.11 RFU) compared to before therapy
(0.57 RFU± 0.85 RFU, P = 0.005).
Results of MMP- and TIMP-measurements are presented
in Table 3.
Correlation of clinical score and MMPs/TIMPs
Strong positive correlations were found between the total
clinical scoring and concentrations of MMP-2 (r = 0.66),
MMP-9 (r = 0.83), TIMP-1 (r = 0.65), TIMP-2 (r = 0.72)
concentrations, MMP-8 activity (r = 0.75) and weakly for
MMP-2 (r = 0.47) activity measured by gelatin zymogra-
phy. All these correlations had a level of significance of
P < 0.01, except MMP-2 zymography (P = 0.036). No
significant correlation was found between the clinical
examination score and MMP-9 zymography (r = 0.30).
Correlations of BALF cytology and MMPs/TIMPs
BAL neutrophil percentages showed no correlation with
the concentrations of MMP-2 (r = 0.39), but significant
correlations with MMP-9 (r = 0.59), TIMP-1 (r = 0.65),
TIMP-2 (r = 0.72) concentrations and MMP-8 activity
(r = 0.78) with P < 0.01. MMP-2 activity measured by
gelatin zymography was also weakly correlated (r = 0.45),
while MMP-9 (r = 0.25) activity was not (P < 0.05).
MMP/TIMP ratios
Significant differences were found for MMP-8 / TIMP-1
(P = 0.002) and MMP-8 / TIMP-2 (P = 0.038) ratios be-
fore and after therapy as shown in Table 4.
Discussion
Pathogenesis of airway remodeling – In human asthma,
activation of fibroblasts leads to increases of ECM mass
by overwhelming fibrosis formation, a process similar to
bronchial remodeling in equine RAO. This is suspected
to be the consequence of a pathologic dysbalance be-
tween proteolytic degradation of ECM components by
MMPs, and excessive tissue repair primarily mediated by
TIMP-1, which can be upregulated very effectively and
Table 2 Mean results ± standard deviation (Min-Max) of clinical
scoring before and after therapy in 10 RAO horses
Parameter Before therapy After therapy P










































* marks significance at P < 0.05
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is capable of cleaving all active MMPs. Elastinolytic and
collagenolytic activity was found in several studies on
human asthma, in particular increased levels of MMP-9
[22, 23], but also MMP-2 [24, 25]. Former studies of our
group showed that this is also true for several equine
pneumopathies including RAO, inflammatory airway
disease (IAD) and chronic interstitial pneumopathy
compared to healthy controls [26, 27]. Compared to
these controls, all horses of the presented study showed
increased levels of MMP 2, 8 and 9 prior to therapy. In-
creased TIMP levels have also been found in humans
suffering from asthma [23, 24, 28, 29] and the same was
found for equine RAO in this study and previous [26, 27].
This may allow the suspicion that fibrosis formation as a
long-term consequence of human asthma and equine
RAO may be the ultimate result of continuous activation
of tissue repair mechanisms or over-repair processes [30].
The most important source of MMP-8, MMP-9 and
TIMP-1 are neutrophils, which are typically increased in
RAO, accounting for more than 25% of BALF cytology by
definition [1]. Therefore, decreases of these enzymes in
accordance with decreasing percentages of neutrophils
can be expected.
Effects of corticosteroids on MMPs and TIMPs - Ac-
cording to the GINA (global initiative for asthma) guide-
lines, inhalative therapy using various corticosteroids
including budesonide is the key factor of asthma therapy
after the control of acute disease exacerbation and is
commonly used for persistent long-term management
[31]. Reduced pulmonary function and increased inflam-
matory mediators are also found in equine RAO during
phases of clinical remission [32] and corticosteroid treat-
ment in combination with ß2-mimetic bronchodilatators
and secretolytic therapy is accepted as the most success-
ful therapy after consequent environmental dust-control
[1]. Inhalative treatment is becoming more and more
popular in equine medicine and results may be more
comparable to what is known in asthmatic patients, so
we chose this route of application for our study. Gluco-
corticoids were shown to slow down the process of
bronchial remodeling by downregulation of elastinolytic
activity and TIMP upregulation at the same time [33],
but other authors could not confirm this observation.
Data of the presented study shows indeed the most sig-
nificant decrease in MMP-9 compared to MMP-2 and 8,
but there were also significant decreases in TIMP-1 and
TIMP-2. Ex vivo studies demonstrated the ability of cor-
ticosteroids to decrease MMP-9 and TIMP-1 levels [34].
In human lung fibrosis, MMP-9 expression could be
inhibited with steroids and immunosuppressants [35].
Fibrosis formation is also a long-term effect of equine
RAO [36, 37] and it might be suspected that TIMPs
decrease in reaction to decreasing MMPs. Nevertheless,
ratios of elastases and TIMPs did not differ before and
after inhalative therapy in combination with environ-
mental dust control in the presented study.
Todorova et al. [30] studied the effect of inhaled bude-
sonide combined with the bronchodilator formoterol on
the metalloproteolytic balance between MMPs and
TIMPs. This combination therapy inhibited upregulation
Fig. 1 Zymography of MMP-2 (lower band) and MMP-9 (upper band)
before (left) and after (right) inhalation therapy in a horse showing
clear improvement in clinical and cytologic data (a) versus a horse,
in which therapy did not lead to significant improvement (b)
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of prostaglandine and TIMP-1 production, MMP-9 levels
and the MMP-9 / TIMP-1 ratio in human lung fibroblasts,
whereas MMP-2 was not affected. Budesonide mono-
therapy required higher concentrations and formoterol
alone had no effects. Therefore, the synergistic effect of
budesonide and formoterol was considered the best option
to reduce enhanced metalloproteolytic activity and may
inhibit or at least reduce pulmonary fibrosis formation in
asthma. We might have enhanced the effect of our therapy
on MMPs in horses, if the budesonide had been combined
with a ß2-agonist like clenbuterol, which is commonly
used in horses. This should be the subject of further
studies. In asthmatic rats sensitized by ovalbumin and
challenged with mist inhalation, steroid treatment not
only reduced MMP-9 and TIMP-1 levels, but also
improved hyperplasia of airway smooth muscle and
basement membrane [38]. Inhalation of budesonide
only influences MMP-9 and TIMP-1 levels in moderate
to severe disease though, no effect of inhaled budesonide
was found in subjects suffering from mild asthma [25].
Obase et al. [39] studied the effects of inhaled budesonide
in children with mild and moderate symptoms of
asthma on MMP-8 and TIMP-1 levels in induced sputum.
Before the beginning of inhalation, MMP-8 was higher in
asthma of moderate severity, TIMP-1 was lower and the
MMP-8/TIMP-1 ratio was higher in mild and moderate
asthma in comparison to healthy childeren. TIMP-1 levels
increased in consequence of budesonide inhalation
leading to normalization of the the MMP-8 / TIMP-1
ratio. Nevertheless, the excessive MMP-8 levels remained
in the airways of children with moderate symptoms.
Therefore, corticosteroids may be capable of controlling
asthma symptoms, but may be insufficient in preventing
the occurrence of airway remodeling involving MMP-8.
Results of the presented study, however, show a significant
reduction in MMP-8 activity after corticosteroid therapy,
although most horses were in disease exacerbation before
starting the inhalation protocol. There were also signifi-
cant reductions in both TIMP concentrations as well as in
the MMP-8 / TIMP-1 and the MMP-8 / TIMP-2 ratios.
This shows that the MMP-8 / TIMP ratios in the horse do
not normalize by upregulation of TIMP, but by downregu-
lation of MMP-8. This seems pleasing and would improve
prognosis in equine disease compared to human asthma,
but further studies should be performed on the role of
MMP-8, as airway remodeling is definitely a long-term
effect of equine RAO leading to irreversible exercise insuf-
ficiency, but fibrosis formation might not be a direct con-
sequence of TIMP overexpression in the horse.
New therapeutic approaches - MMPs themselves have
been discussed as an ideal target for new therapeutic
approaches as they play an active role in disease patho-
physiology [40]. Inhibition of MMP activity has been
studied in human cancer. Although this was not suc-
cessful [41], new data suggests that selective inhibitors
might find a role in acute and chronic anti-inflammatory
therapy after all [42]. This includes asthma, where reduced
airway inflammation and hyperresponsiveness was
reported after local bronchial application of synthetic
TIMP-2 [43]. TIMP-2 downregulated MMP-2 activity
[44]. In addition to their antibiotic acitivity, tetracyclines
act as effective MMP inhibitors. Doxycycline was studied
in asthma models including different species [10, 45, 46].
After oral administration in mice, it reduced airway
inflammation and hyperresponsiveness as well as
MMP-9 expression. Further studies have shown that
MMP-inhibition also decreases goblet cell hyperplasia,
another component of airway remodeling in asthma
[47], whichh is also known for equine RAO. In the
horse, in-vitro studies showed reductions of proteolytic
activity using acetylcysteine, pentamidine and diminazene
[14, 48]. The clinical application of synthetic TIMPs in
Table 3 MMP-2, MMP-9, TIMP-1 and TIMP-2 ELISA and MMP-8 fluorimetry measurements, the results are expressed as mean ± SD
n Before therapy After therapy P-value
MMP-2 ELISA [pg/ml] 10 4.93 ± 0.91 3.54 ± 0.71 0.005
MMP-9 ELISA [ng/ml] 10 414.59 ± 119.6 282.29 ± 101.19 0.005
TIMP-1 ELISA [pg/ml] 10 308.80 ± 7.44 249.78 ± 59.56 0.005
TIMP-2 ELISA [ng/ml] 10 26.20 ± 1.49 18.76 ± 2.79 0.002
MMP-8 Fluorimetry [RFU] 10 0.57 ± 0.85 0.1 ± 0.11 0.005
MMP-2 zymography 10 12570.98 ± 9164.32 5827.45 ± 5250.42 0.028
MMP-9 zymography 10 11176.68 ± 11255.3 2942.95 ± 2440.24 0.022
Table 4 MMP/TIMP ratios before and after therapy (n = 10)
MMP-2/ TIMP-1 MMP-2/ TIMP 2 MMP-9/ TIMP-1 MMP-9/ TIMP-2 MMP-8/ TIMP-1 MMP-8/ TIMP-2
Before therapy 0.016 0.188 1.343 15.824 0.002 0.022
After therapy 0.014 0.188 1.130 15.047 0.000* 0.005*
The (*) shows significance at P < 0.05
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RAO horses is currently under consideration by our
group.
Limitations - To our knowledge, this is the first study
on the course of MMPs in RAO affected horses and a
clinical trial, but we were faced with several limitations,
so unintentional bias may have occurred at several
points. Due to the fact that privately owned horses were
included to the study, it was doubtful if stabling of all
horses at their home stables was actually in a low-dust
environment, as most horses were still in exacerbation
and had increased MMPs at the beginning of therapy.
The effect of therapy may therefore be based on the
combined effect of inhalative glucocorticoid therapy and
environmental dust reduction under clinic conditions,
with the effect of the latter being quite variable. Even if
horses had been stabled on wood shavings and fed wet
hay, they may have come from a very dusty environment
apart from these two conditions for enrolment in the
study. A second group subjected to a low-dust-
environment in the clinic only would have been prefera-
ble to control this effect and was planned to be included
in the study, but unfortunately, not enough owners
agreed to this protocol. Therefore, the actual bias caused
by this is hard to assess. Another time-point of sampling
after a few days of low-dust-environment before starting
inhalation therapy would have been helpful as well, but
again, owners wished for hospitalization as short as pos-
sible. On the other hand, it was not the aim of this study
to prove the therapeutic effect of neither environmental
dust reduction, which is commonly acceptected [1] nor
inhaled budesonide, which has also already been pub-
lished [49], but to study the course of MMPs and TIMPs
under clinical improvement to evaluate their usefulness
as biomarkers and correlation with clinical and cyto-
logical findings. Clinical scoring and even the quantita-
tive tests may have been subject to bias as well. The
clinical scoring was done by two independent observers,
but these were not blinded to horses’enrolment in the
study and the time-point as before or after therapy,
which was due to the fact that subjects enrolled were
clinic patients. Endoscopy and cytology was done by one
observer and images scored by another later on randomly
and blinded. ELISAs and zymography were performed,
when all samples had been collected and stored, also
randomly and blinded.
Conclusion
Despite the difficulties discussed above, the results of
the presented study suggest that developing new thera-
peutic approaches to correct the misbalance between
MMPs and TIMPs might be promising for treatment of
asthma and equine RAO, which shares many features
with human asthma disease. Due to their various effects
in different organ systems, it seems safer to target
MMPs actually relevant in this disease specifically and to
use an inhalative approach to reach high local levels of
the drug, while the remaining organism remains un-
affected. In chronic pneumopathies, targeting MMP-2 and
MMP-8, but in particular MMP-9 might be of therapeutic
value [50]. First attempts in this direction have been taken
in treating cancer, but less data is available on inhibition
of MMP activity in chronic pneumopathies [51].
To our knowledge, TIMP-1 or TIMP-2 expression in
equine RAO has not been studied so far. Studies in
horses on the effect of inhaled glucocorticoids on MMPs
or TIMPs have not been published either. Therefore, this
is the first clinical study to show a correlation of MMP
and TIMP levels to clinical findings and cytology. Parallels
to results presented in papers on humans and laboratory
animals allow the suspicion that the same mechanisms
might apply in the horse regarding the effects of glucocor-
ticoids, but further studies including a control group have
to be performed to differentiate a possible therapeutic
effect between glucocorticoid inhalation and envirnon-
mental dust reduction in horses affected by RAO.
Endnotes
1Lidocaine, bela-Pharm GmbH, Vechta, Germany
2Silicone Bronchoalveolar Lavage Catheter 300 cm,
Smiths Medical ASD, Inc, USA
3Phosphate buffered saline, Lonza, Verviers, Belgium;d-
Table Top Refrigerated Centrifuge Hermle Z326K,
Hermle Labortechnik GmbH, Germany
4Gelatin zymogram gels, Life technologies, USA
5electrophoresis device XCell, Novex Experimental
Technology, Japan
6ImageJ v1.47, Wayne Rasband, NIH, USA
7equine MMP-2 kit, USCN Life Science Inc., China
8equine MMP-2 kit, USCN Life Science Inc., China
9equine MMP-9 kit, USCN Life Science Inc., China
10equine TIMP-1 kit, USCN Life Science Inc., China
11equine TIMP-2 kit, USCN Life Science Inc., China
12ELISA microplate reader, BioRad Laboratories, USA
13SensolyteTM 520 MMP-8 Assay Kit, Anaspec, Inc.
Fermont, USA
14Pulmicort™ suspension, Astra Zeneca, Germany
15SaHoMa II mobile ultrasonic nebulizer, NEBU-TEC
International, Germany
16SPSS Statistics, Version 17.0 released 2008, SPSS
Inc., USA
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